Neuronal mechanisms of active (rapid eye movement) sleep induced by microinjections of hypocretin into the nucleus pontis oralis of the cat.
Hypocretinergic (orexinergic) neurons in the hypothalamus project to the nucleus pontis oralis, a nucleus which plays a crucial role in the generation of active (rapid eye movement) sleep. We recently reported that the microinjection of hypocretin into the nucleus pontis oralis of chronically-instrumented, unanesthetized cats induces a behavioral state that is comparable to naturally-occurring active sleep. The present study examined the intracellular signaling pathways underlying the active sleep-inducing effects of hypocretin. Accordingly, hypocretin-1, a protein kinase C inhibitor and a protein kinase A inhibitor were injected into the nucleus pontis oralis in selected combinations in order to determine their effects on sleep and waking states of chronically instrumented, unanesthetized cats. Microinjections of hypocretin-1 into the nucleus pontis oralis elicited active sleep with a short latency. However, a pre-injection of bisindolylmaleimide-I, a protein kinase C-specific inhibitor, completely blocked the active sleep-inducing effects of hypocretin-1. The combined injection of bisindolylmaleimide-I and hypocretin-1 significantly increased the latency to active sleep induced by hypocretin-1; it also abolished the increase in the time spent in active sleep induced by hypocretin-1. On the other hand, the injection of 2'5'-dideoxyadenosine, an adenylyl cyclase inhibitor, did not block the occurrence of active sleep by hypocretin-1. We conclude that the active sleep-inducing effect of hypocretin in the nucleus pontis oralis is mediated by intracellular signaling pathways that act via G-protein stimulation of protein kinase C.
Xi
M-C
MC
WebSciences International, 1251 Westwood Boulevard, Los Angeles, CA 90024, USA.
Chase
M H
MH
D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal; D002415:Cats; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004576:Electromyography / Q000379:methods; D004585:Electrooculography / Q000379:methods; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007211:Indoles / Q000494:pharmacology; D047908:Intracellular Signaling Peptides and Proteins / Q000494:pharmacology*; D008301:Maleimides / Q000494:pharmacology; D008845:Microinjections / Q000379:methods; D009479:Neuropeptides / Q000494:pharmacology*; D000068797:Orexins; D011149:Pons / Q000187:drug effects* / Q000502:physiology; D011930:Reaction Time / Q000187:drug effects; D012895:Sleep, REM / Q000187:drug effects*
D004791:Enzyme Inhibitors; D007211:Indoles; D047908:Intracellular Signaling Peptides and Proteins; D008301:Maleimides; D009479:Neuropeptides; D000068797:Orexins; C070515:bisindolylmaleimide I